ASTRO 2017: Highlights in Advanced Lung Cancer

October 3, 2017
Maria Werner-Wasik, MD

This video highlights studies on advanced lung cancer with practice-changing potential presented at the 2017 ASTRO Annual Meeting.

In this video, Maria Werner-Wasik, MD, of Thomas Jefferson University Hospital in Philadelphia, discusses selected studies on the treatment of lung cancer presented at the 2017 American Society for Radiation Oncology (ASTRO) Annual Meeting, held September 24–27 in San Diego.

Werner-Wasik was the discussant for a session on lung cancer that featured the following abstracts, which were selected for their importance and practice-changing potential:

Abstract 223: Quality of life (QOL) outcomes in a phase III randomized trial of optimization of treatment of advanced non–small-cell lung cancer using radiotherapy and chemotherapy: IAEA multicentric randomized phase III study (NCT00864331)

Abstract LBA-3: Consolidative radiotherapy for limited metastatic non–small-cell lung cancer (NSCLC): a randomized phase II trial

Abstract LBA-4: PACIFIC: A double-blind, placebo-controlled phase III study of durvalumab as consolidation therapy after chemoradiation in patients with locally advanced, unresectable NSCLC

Abstract 227: Long-term results of RTOG 0617; a randomized phase III comparison of standard dose vs high-dose conformal chemoradiotherapy +/- cetuximab for stage III non–small-cell lung cancer

Abstract 33: Long-term follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): A randomized phase II study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage I peripheral non–small-cell lung cancer